Company intelligence / Profile preview

Noema Pharma

Basel, Basel-Stadt, Switzerlandnoemapharma.com ↗

Ownership: Private
Employees: ~75
Development stage: Phase 2

Overview

Noema Pharma has four active clinical programs in Phase 2 trials targeting severe central nervous system disorders. Lead assets include basimglurant for seizures in TSC and trigeminal neuralgia pain, gemlapodect for Tourette syndrome and stuttering, and NOE‑115 for vasomotor/menopausal symptoms. All are expected to have key data readouts in late 2024 or early 2025. The company’s approach leverages novel mechanisms such as mGluR modulation and PDE10A inhibition to address high unmet needs in both rare/orphan and broader CNS populations.

Therapeutic areas: Women's HealthNeurology
Modalities: Small molecules (e.g., negative allosteric modulators, PDE10A inhibitors, monoamine modulators)
Industry: Biotech

Drug pipeline

4 assets

basimglurant

3 more assets in the full pipeline.

Request access →

Partnerships

Roche—lead assets licensed from Roche.

Beyond the preview

Go deeper on Noema Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Noema Pharma.

Explore the full profile